FIELD: medicine, pharmaceutics.
SUBSTANCE: present invention refers to immunology. What is presented is a lymphotoxin-alpha (LTα) antibody, including chimeric and humanised versions thereof. Where are disclosed compositions containing it, using it for preparing a medication for autoimmune disorders, a method of inhibiting ex vivo lymphotoxin-alpha activated cell proliferation with using the antibody under the invention, as well as a nucleic acid, an expression vector, a host cell and a method of producing the antibody that proceeds from using them.
EFFECT: present invention can find further application in a therapy of the autoimmune diseases.
51 cl, 21 ex, 27 dwg, 7 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| NOVEL ANTIBODIES | 2008 |
|
RU2490277C2 |
| DOUBLE SPECIFICITY ANTIBODIES | 2014 |
|
RU2732032C2 |
| HUMANISED ANTIBODIES TO Toll-LIKE RECEPTORS 2 AND THEIR APPLICATIONS | 2010 |
|
RU2563344C2 |
| PROTEIN COMPLEXES CONTAINING SUPERHELIX AND/OR BANDING, AND THEIR USE | 2010 |
|
RU2573915C2 |
| ANTIBODIES TO CD40 AND METHODS OF USE THEREOF | 2016 |
|
RU2715597C2 |
| PROTEINS BINDING PROSTAGLANDIN E2 AND USING THEM | 2009 |
|
RU2559525C2 |
| TREATMENT OF CANCER WITH HER2XCD3 BISPECIFIC ANTIBODIES IN COMBINATION WITH ANTI-HER2 MAB | 2020 |
|
RU2793296C1 |
| IL-6 ANTAGONISTS AND USES THEREOF | 2013 |
|
RU2670943C9 |
| METHOD OF TREATING VISCERAL PAIN BY ADMINISTERING ANTAGONIST ANTIBODIES AGAINST CALCITONIN GENE-RELATED PEPTIDE | 2010 |
|
RU2535074C2 |
| METHODS OF TREATING DIABETES WITH DLL4 ANTAGONISTS | 2011 |
|
RU2587624C2 |
